Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Australian Clinical Labs Ltd ( (AU:ACL) ) has provided an update.
Australian Clinical Labs Limited announced the resignation of Dr. Leanne Rowe AM from its Board, effective immediately, due to personal reasons. Dr. Rowe, who joined the Board during the company’s IPO in April 2021, brought significant medical and leadership expertise, contributing greatly to the Board’s skill set and supporting the senior executive team. Her departure is noted as a loss for the company, which expressed gratitude for her contributions and wished her well in future endeavors.
The most recent analyst rating on (AU:ACL) stock is a Hold with a A$2.50 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
More about Australian Clinical Labs Ltd
Australian Clinical Labs (ACL) is a prominent Australian private provider of pathology services. Their NATA accredited laboratories conduct a wide array of pathology tests annually for various clients, including doctors, specialists, patients, hospitals, and corporate clients. ACL is recognized as one of the largest private hospital pathology businesses in the country, focusing on integrating talented professionals with innovative technologies to enhance decision-making and improve patient outcomes.
Average Trading Volume: 1,020,307
Technical Sentiment Signal: Sell
Current Market Cap: A$495.4M
See more data about ACL stock on TipRanks’ Stock Analysis page.